nodes	percent_of_prediction	percent_of_DWPC	metapath
Tretinoin—CYP4A11—Cisplatin—testicular cancer	0.137	0.22	CbGbCtD
Tretinoin—CYP2C18—Ifosfamide—testicular cancer	0.124	0.199	CbGbCtD
Tretinoin—CYP2A6—Ifosfamide—testicular cancer	0.0602	0.0966	CbGbCtD
Tretinoin—CYP3A7—Ifosfamide—testicular cancer	0.0411	0.066	CbGbCtD
Tretinoin—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0411	0.066	CbGbCtD
Tretinoin—CYP2B6—Ifosfamide—testicular cancer	0.0392	0.0629	CbGbCtD
Tretinoin—NR0B1—seminiferous tubule of testis—testicular cancer	0.0344	0.292	CbGeAlD
Tretinoin—CYP3A5—Ifosfamide—testicular cancer	0.0309	0.0495	CbGbCtD
Tretinoin—CYP2C8—Ifosfamide—testicular cancer	0.0297	0.0476	CbGbCtD
Tretinoin—CYP2C9—Ifosfamide—testicular cancer	0.0207	0.0332	CbGbCtD
Tretinoin—CYP2B6—Cisplatin—testicular cancer	0.0191	0.0306	CbGbCtD
Tretinoin—CYP3A5—Etoposide—testicular cancer	0.0148	0.0237	CbGbCtD
Tretinoin—CYP2C8—Etoposide—testicular cancer	0.0142	0.0228	CbGbCtD
Tretinoin—CYP2B6—Doxorubicin—testicular cancer	0.0128	0.0205	CbGbCtD
Tretinoin—CYP3A4—Ifosfamide—testicular cancer	0.012	0.0193	CbGbCtD
Tretinoin—CYP2C9—Cisplatin—testicular cancer	0.0101	0.0162	CbGbCtD
Tretinoin—CYP3A4—Vinblastine—testicular cancer	0.00638	0.0102	CbGbCtD
Tretinoin—CYP3A4—Etoposide—testicular cancer	0.00575	0.00923	CbGbCtD
Tretinoin—RARRES1—seminal vesicle—testicular cancer	0.00469	0.0398	CbGeAlD
Tretinoin—CYP3A4—Doxorubicin—testicular cancer	0.00392	0.0063	CbGbCtD
Tretinoin—ALDH1A2—embryo—testicular cancer	0.00383	0.0325	CbGeAlD
Tretinoin—CRABP1—embryo—testicular cancer	0.00369	0.0314	CbGeAlD
Tretinoin—CRABP2—embryo—testicular cancer	0.00334	0.0284	CbGeAlD
Tretinoin—CRABP2—seminal vesicle—testicular cancer	0.00314	0.0267	CbGeAlD
Tretinoin—NR0B1—gonad—testicular cancer	0.00291	0.0248	CbGeAlD
Tretinoin—ALDH1A1—embryo—testicular cancer	0.00278	0.0236	CbGeAlD
Tretinoin—RARRES1—female gonad—testicular cancer	0.00275	0.0234	CbGeAlD
Tretinoin—ALDH1A1—seminal vesicle—testicular cancer	0.00261	0.0222	CbGeAlD
Tretinoin—ALDH1A2—gonad—testicular cancer	0.0026	0.0221	CbGeAlD
Tretinoin—CRABP1—gonad—testicular cancer	0.00251	0.0213	CbGeAlD
Tretinoin—RARRES1—testis—testicular cancer	0.00244	0.0207	CbGeAlD
Tretinoin—NR0B1—female gonad—testicular cancer	0.00237	0.0201	CbGeAlD
Tretinoin—CRABP2—gonad—testicular cancer	0.00227	0.0193	CbGeAlD
Tretinoin—ALDH1A2—female gonad—testicular cancer	0.00211	0.0179	CbGeAlD
Tretinoin—NR0B1—testis—testicular cancer	0.0021	0.0178	CbGeAlD
Tretinoin—ALDH1A1—gonad—testicular cancer	0.00189	0.016	CbGeAlD
Tretinoin—ALDH1A2—testis—testicular cancer	0.00187	0.0159	CbGeAlD
Tretinoin—ALDH1A1—Podofilox—Etoposide—testicular cancer	0.00187	0.333	CbGdCrCtD
Tretinoin—ALDH1A1—Teniposide—Etoposide—testicular cancer	0.00187	0.333	CbGdCrCtD
Tretinoin—CRABP2—female gonad—testicular cancer	0.00184	0.0157	CbGeAlD
Tretinoin—RXRA—female gonad—testicular cancer	0.00183	0.0156	CbGeAlD
Tretinoin—CRABP1—testis—testicular cancer	0.00181	0.0153	CbGeAlD
Tretinoin—RARRES1—lymph node—testicular cancer	0.00177	0.015	CbGeAlD
Tretinoin—RARB—female gonad—testicular cancer	0.00165	0.014	CbGeAlD
Tretinoin—CRABP2—testis—testicular cancer	0.00163	0.0139	CbGeAlD
Tretinoin—RARA—gonad—testicular cancer	0.00155	0.0132	CbGeAlD
Tretinoin—ALDH1A1—female gonad—testicular cancer	0.00153	0.013	CbGeAlD
Tretinoin—CYP2A6—seminal vesicle—testicular cancer	0.00152	0.0129	CbGeAlD
Tretinoin—RXRB—female gonad—testicular cancer	0.00151	0.0129	CbGeAlD
Tretinoin—RXRG—testis—testicular cancer	0.00143	0.0121	CbGeAlD
Tretinoin—ALDH1A1—testis—testicular cancer	0.00136	0.0116	CbGeAlD
Tretinoin—ALDH1A2—lymph node—testicular cancer	0.00136	0.0115	CbGeAlD
Tretinoin—RARG—female gonad—testicular cancer	0.00134	0.0114	CbGeAlD
Tretinoin—RXRB—testis—testicular cancer	0.00134	0.0114	CbGeAlD
Tretinoin—RARA—female gonad—testicular cancer	0.00126	0.0107	CbGeAlD
Tretinoin—RARG—testis—testicular cancer	0.00119	0.0101	CbGeAlD
Tretinoin—RARA—testis—testicular cancer	0.00112	0.00952	CbGeAlD
Tretinoin—RARB—lymph node—testicular cancer	0.00106	0.009	CbGeAlD
Tretinoin—ALDH1A1—lymph node—testicular cancer	0.000987	0.00838	CbGeAlD
Tretinoin—ALDH1A1—Idarubicin—Epirubicin—testicular cancer	0.000974	0.174	CbGdCrCtD
Tretinoin—ALDH1A1—Idarubicin—Doxorubicin—testicular cancer	0.000901	0.161	CbGdCrCtD
Tretinoin—RARG—lymph node—testicular cancer	0.000864	0.00734	CbGeAlD
Tretinoin—RARA—lymph node—testicular cancer	0.000812	0.0069	CbGeAlD
Tretinoin—CYP2B6—gonad—testicular cancer	0.000552	0.00469	CbGeAlD
Tretinoin—CYP1A1—female gonad—testicular cancer	0.000462	0.00393	CbGeAlD
Tretinoin—CYP3A5—female gonad—testicular cancer	0.000452	0.00384	CbGeAlD
Tretinoin—CYP2C8—testis—testicular cancer	0.000444	0.00377	CbGeAlD
Tretinoin—CYP2B6—testis—testicular cancer	0.000398	0.00338	CbGeAlD
Tretinoin—CYP1A1—lymph node—testicular cancer	0.000297	0.00252	CbGeAlD
Tretinoin—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	8.4e-05	0.000331	CcSEcCtD
Tretinoin—Vomiting—Ifosfamide—testicular cancer	8.39e-05	0.00033	CcSEcCtD
Tretinoin—Hypersensitivity—Cisplatin—testicular cancer	8.38e-05	0.00033	CcSEcCtD
Tretinoin—Renal failure—Doxorubicin—testicular cancer	8.33e-05	0.000328	CcSEcCtD
Tretinoin—Rash—Ifosfamide—testicular cancer	8.32e-05	0.000328	CcSEcCtD
Tretinoin—Dermatitis—Ifosfamide—testicular cancer	8.31e-05	0.000327	CcSEcCtD
Tretinoin—Erythema multiforme—Methotrexate—testicular cancer	8.3e-05	0.000327	CcSEcCtD
Tretinoin—Neuropathy peripheral—Doxorubicin—testicular cancer	8.3e-05	0.000327	CcSEcCtD
Tretinoin—Urticaria—Etoposide—testicular cancer	8.28e-05	0.000326	CcSEcCtD
Tretinoin—Haemoglobin—Epirubicin—testicular cancer	8.26e-05	0.000326	CcSEcCtD
Tretinoin—Stomatitis—Doxorubicin—testicular cancer	8.26e-05	0.000325	CcSEcCtD
Tretinoin—Body temperature increased—Etoposide—testicular cancer	8.23e-05	0.000325	CcSEcCtD
Tretinoin—Abdominal pain—Etoposide—testicular cancer	8.23e-05	0.000325	CcSEcCtD
Tretinoin—Urinary tract infection—Doxorubicin—testicular cancer	8.23e-05	0.000325	CcSEcCtD
Tretinoin—Conjunctivitis—Doxorubicin—testicular cancer	8.23e-05	0.000325	CcSEcCtD
Tretinoin—Haemorrhage—Epirubicin—testicular cancer	8.22e-05	0.000324	CcSEcCtD
Tretinoin—Hepatitis—Epirubicin—testicular cancer	8.22e-05	0.000324	CcSEcCtD
Tretinoin—Eye disorder—Methotrexate—testicular cancer	8.21e-05	0.000323	CcSEcCtD
Tretinoin—Tinnitus—Methotrexate—testicular cancer	8.19e-05	0.000323	CcSEcCtD
Tretinoin—Hypoaesthesia—Epirubicin—testicular cancer	8.18e-05	0.000322	CcSEcCtD
Tretinoin—Asthenia—Cisplatin—testicular cancer	8.16e-05	0.000322	CcSEcCtD
Tretinoin—Pharyngitis—Epirubicin—testicular cancer	8.16e-05	0.000321	CcSEcCtD
Tretinoin—Sweating—Doxorubicin—testicular cancer	8.12e-05	0.00032	CcSEcCtD
Tretinoin—Urinary tract disorder—Epirubicin—testicular cancer	8.12e-05	0.00032	CcSEcCtD
Tretinoin—Oedema peripheral—Epirubicin—testicular cancer	8.1e-05	0.000319	CcSEcCtD
Tretinoin—Haematuria—Doxorubicin—testicular cancer	8.08e-05	0.000318	CcSEcCtD
Tretinoin—Urethral disorder—Epirubicin—testicular cancer	8.06e-05	0.000318	CcSEcCtD
Tretinoin—Epistaxis—Doxorubicin—testicular cancer	7.99e-05	0.000315	CcSEcCtD
Tretinoin—Angiopathy—Methotrexate—testicular cancer	7.97e-05	0.000314	CcSEcCtD
Tretinoin—Sinusitis—Doxorubicin—testicular cancer	7.95e-05	0.000313	CcSEcCtD
Tretinoin—Visual impairment—Epirubicin—testicular cancer	7.92e-05	0.000312	CcSEcCtD
Tretinoin—Agranulocytosis—Doxorubicin—testicular cancer	7.91e-05	0.000312	CcSEcCtD
Tretinoin—Chills—Methotrexate—testicular cancer	7.88e-05	0.000311	CcSEcCtD
Tretinoin—Nausea—Ifosfamide—testicular cancer	7.83e-05	0.000309	CcSEcCtD
Tretinoin—Diarrhoea—Cisplatin—testicular cancer	7.78e-05	0.000307	CcSEcCtD
Tretinoin—Erythema multiforme—Epirubicin—testicular cancer	7.77e-05	0.000306	CcSEcCtD
Tretinoin—Alopecia—Methotrexate—testicular cancer	7.76e-05	0.000306	CcSEcCtD
Tretinoin—Mental disorder—Methotrexate—testicular cancer	7.69e-05	0.000303	CcSEcCtD
Tretinoin—Eye disorder—Epirubicin—testicular cancer	7.68e-05	0.000303	CcSEcCtD
Tretinoin—Hypersensitivity—Etoposide—testicular cancer	7.67e-05	0.000302	CcSEcCtD
Tretinoin—Tinnitus—Epirubicin—testicular cancer	7.66e-05	0.000302	CcSEcCtD
Tretinoin—Malnutrition—Methotrexate—testicular cancer	7.65e-05	0.000301	CcSEcCtD
Tretinoin—Erythema—Methotrexate—testicular cancer	7.65e-05	0.000301	CcSEcCtD
Tretinoin—Haemoglobin—Doxorubicin—testicular cancer	7.64e-05	0.000301	CcSEcCtD
Tretinoin—Flushing—Epirubicin—testicular cancer	7.63e-05	0.000301	CcSEcCtD
Tretinoin—Haemorrhage—Doxorubicin—testicular cancer	7.6e-05	0.0003	CcSEcCtD
Tretinoin—Hepatitis—Doxorubicin—testicular cancer	7.6e-05	0.0003	CcSEcCtD
Tretinoin—Hypoaesthesia—Doxorubicin—testicular cancer	7.57e-05	0.000298	CcSEcCtD
Tretinoin—Pharyngitis—Doxorubicin—testicular cancer	7.55e-05	0.000297	CcSEcCtD
Tretinoin—Urinary tract disorder—Doxorubicin—testicular cancer	7.51e-05	0.000296	CcSEcCtD
Tretinoin—Oedema peripheral—Doxorubicin—testicular cancer	7.49e-05	0.000295	CcSEcCtD
Tretinoin—Asthenia—Etoposide—testicular cancer	7.47e-05	0.000295	CcSEcCtD
Tretinoin—Angiopathy—Epirubicin—testicular cancer	7.46e-05	0.000294	CcSEcCtD
Tretinoin—Urethral disorder—Doxorubicin—testicular cancer	7.45e-05	0.000294	CcSEcCtD
Tretinoin—Back pain—Methotrexate—testicular cancer	7.4e-05	0.000291	CcSEcCtD
Tretinoin—Chills—Epirubicin—testicular cancer	7.37e-05	0.000291	CcSEcCtD
Tretinoin—Pruritus—Etoposide—testicular cancer	7.37e-05	0.00029	CcSEcCtD
Tretinoin—Arrhythmia—Epirubicin—testicular cancer	7.34e-05	0.000289	CcSEcCtD
Tretinoin—Visual impairment—Doxorubicin—testicular cancer	7.33e-05	0.000289	CcSEcCtD
Tretinoin—Alopecia—Epirubicin—testicular cancer	7.26e-05	0.000286	CcSEcCtD
Tretinoin—Vomiting—Cisplatin—testicular cancer	7.23e-05	0.000285	CcSEcCtD
Tretinoin—Vision blurred—Methotrexate—testicular cancer	7.21e-05	0.000284	CcSEcCtD
Tretinoin—Mental disorder—Epirubicin—testicular cancer	7.2e-05	0.000284	CcSEcCtD
Tretinoin—Erythema multiforme—Doxorubicin—testicular cancer	7.19e-05	0.000283	CcSEcCtD
Tretinoin—Rash—Cisplatin—testicular cancer	7.17e-05	0.000283	CcSEcCtD
Tretinoin—Dermatitis—Cisplatin—testicular cancer	7.16e-05	0.000282	CcSEcCtD
Tretinoin—Malnutrition—Epirubicin—testicular cancer	7.15e-05	0.000282	CcSEcCtD
Tretinoin—Erythema—Epirubicin—testicular cancer	7.15e-05	0.000282	CcSEcCtD
Tretinoin—Diarrhoea—Etoposide—testicular cancer	7.13e-05	0.000281	CcSEcCtD
Tretinoin—Eye disorder—Doxorubicin—testicular cancer	7.11e-05	0.00028	CcSEcCtD
Tretinoin—Ill-defined disorder—Methotrexate—testicular cancer	7.09e-05	0.00028	CcSEcCtD
Tretinoin—Tinnitus—Doxorubicin—testicular cancer	7.09e-05	0.000279	CcSEcCtD
Tretinoin—Anaemia—Methotrexate—testicular cancer	7.07e-05	0.000278	CcSEcCtD
Tretinoin—Flushing—Doxorubicin—testicular cancer	7.06e-05	0.000278	CcSEcCtD
Tretinoin—Flatulence—Epirubicin—testicular cancer	7.05e-05	0.000278	CcSEcCtD
Tretinoin—Tension—Epirubicin—testicular cancer	7.02e-05	0.000277	CcSEcCtD
Tretinoin—Nervousness—Epirubicin—testicular cancer	6.95e-05	0.000274	CcSEcCtD
Tretinoin—Back pain—Epirubicin—testicular cancer	6.92e-05	0.000273	CcSEcCtD
Tretinoin—Angiopathy—Doxorubicin—testicular cancer	6.9e-05	0.000272	CcSEcCtD
Tretinoin—Malaise—Methotrexate—testicular cancer	6.89e-05	0.000272	CcSEcCtD
Tretinoin—Dizziness—Etoposide—testicular cancer	6.89e-05	0.000271	CcSEcCtD
Tretinoin—Chills—Doxorubicin—testicular cancer	6.82e-05	0.000269	CcSEcCtD
Tretinoin—Arrhythmia—Doxorubicin—testicular cancer	6.79e-05	0.000268	CcSEcCtD
Tretinoin—Nausea—Cisplatin—testicular cancer	6.75e-05	0.000266	CcSEcCtD
Tretinoin—Vision blurred—Epirubicin—testicular cancer	6.74e-05	0.000266	CcSEcCtD
Tretinoin—Alopecia—Doxorubicin—testicular cancer	6.72e-05	0.000265	CcSEcCtD
Tretinoin—Cough—Methotrexate—testicular cancer	6.67e-05	0.000263	CcSEcCtD
Tretinoin—Mental disorder—Doxorubicin—testicular cancer	6.66e-05	0.000263	CcSEcCtD
Tretinoin—Ill-defined disorder—Epirubicin—testicular cancer	6.64e-05	0.000262	CcSEcCtD
Tretinoin—Convulsion—Methotrexate—testicular cancer	6.62e-05	0.000261	CcSEcCtD
Tretinoin—Vomiting—Etoposide—testicular cancer	6.62e-05	0.000261	CcSEcCtD
Tretinoin—Erythema—Doxorubicin—testicular cancer	6.62e-05	0.000261	CcSEcCtD
Tretinoin—Malnutrition—Doxorubicin—testicular cancer	6.62e-05	0.000261	CcSEcCtD
Tretinoin—Anaemia—Epirubicin—testicular cancer	6.61e-05	0.000261	CcSEcCtD
Tretinoin—Agitation—Epirubicin—testicular cancer	6.57e-05	0.000259	CcSEcCtD
Tretinoin—Rash—Etoposide—testicular cancer	6.57e-05	0.000259	CcSEcCtD
Tretinoin—Dermatitis—Etoposide—testicular cancer	6.56e-05	0.000259	CcSEcCtD
Tretinoin—Headache—Etoposide—testicular cancer	6.53e-05	0.000257	CcSEcCtD
Tretinoin—Flatulence—Doxorubicin—testicular cancer	6.52e-05	0.000257	CcSEcCtD
Tretinoin—Myalgia—Methotrexate—testicular cancer	6.51e-05	0.000257	CcSEcCtD
Tretinoin—Chest pain—Methotrexate—testicular cancer	6.51e-05	0.000257	CcSEcCtD
Tretinoin—Arthralgia—Methotrexate—testicular cancer	6.51e-05	0.000257	CcSEcCtD
Tretinoin—Tension—Doxorubicin—testicular cancer	6.5e-05	0.000256	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	6.46e-05	0.000255	CcSEcCtD
Tretinoin—Malaise—Epirubicin—testicular cancer	6.45e-05	0.000254	CcSEcCtD
Tretinoin—Discomfort—Methotrexate—testicular cancer	6.43e-05	0.000253	CcSEcCtD
Tretinoin—Nervousness—Doxorubicin—testicular cancer	6.43e-05	0.000253	CcSEcCtD
Tretinoin—Syncope—Epirubicin—testicular cancer	6.42e-05	0.000253	CcSEcCtD
Tretinoin—Back pain—Doxorubicin—testicular cancer	6.4e-05	0.000252	CcSEcCtD
Tretinoin—Palpitations—Epirubicin—testicular cancer	6.32e-05	0.000249	CcSEcCtD
Tretinoin—Confusional state—Methotrexate—testicular cancer	6.29e-05	0.000248	CcSEcCtD
Tretinoin—Loss of consciousness—Epirubicin—testicular cancer	6.29e-05	0.000248	CcSEcCtD
Tretinoin—Cough—Epirubicin—testicular cancer	6.24e-05	0.000246	CcSEcCtD
Tretinoin—Anaphylactic shock—Methotrexate—testicular cancer	6.24e-05	0.000246	CcSEcCtD
Tretinoin—Vision blurred—Doxorubicin—testicular cancer	6.24e-05	0.000246	CcSEcCtD
Tretinoin—Convulsion—Epirubicin—testicular cancer	6.2e-05	0.000244	CcSEcCtD
Tretinoin—Infection—Methotrexate—testicular cancer	6.2e-05	0.000244	CcSEcCtD
Tretinoin—Nausea—Etoposide—testicular cancer	6.19e-05	0.000244	CcSEcCtD
Tretinoin—Hypertension—Epirubicin—testicular cancer	6.18e-05	0.000243	CcSEcCtD
Tretinoin—Ill-defined disorder—Doxorubicin—testicular cancer	6.14e-05	0.000242	CcSEcCtD
Tretinoin—Nervous system disorder—Methotrexate—testicular cancer	6.12e-05	0.000241	CcSEcCtD
Tretinoin—Anaemia—Doxorubicin—testicular cancer	6.12e-05	0.000241	CcSEcCtD
Tretinoin—Thrombocytopenia—Methotrexate—testicular cancer	6.11e-05	0.000241	CcSEcCtD
Tretinoin—Arthralgia—Epirubicin—testicular cancer	6.09e-05	0.00024	CcSEcCtD
Tretinoin—Myalgia—Epirubicin—testicular cancer	6.09e-05	0.00024	CcSEcCtD
Tretinoin—Chest pain—Epirubicin—testicular cancer	6.09e-05	0.00024	CcSEcCtD
Tretinoin—Agitation—Doxorubicin—testicular cancer	6.08e-05	0.00024	CcSEcCtD
Tretinoin—Anxiety—Epirubicin—testicular cancer	6.07e-05	0.000239	CcSEcCtD
Tretinoin—Skin disorder—Methotrexate—testicular cancer	6.06e-05	0.000239	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	6.05e-05	0.000238	CcSEcCtD
Tretinoin—Hyperhidrosis—Methotrexate—testicular cancer	6.03e-05	0.000238	CcSEcCtD
Tretinoin—Discomfort—Epirubicin—testicular cancer	6.02e-05	0.000237	CcSEcCtD
Tretinoin—Malaise—Doxorubicin—testicular cancer	5.97e-05	0.000235	CcSEcCtD
Tretinoin—Dry mouth—Epirubicin—testicular cancer	5.96e-05	0.000235	CcSEcCtD
Tretinoin—Anorexia—Methotrexate—testicular cancer	5.95e-05	0.000234	CcSEcCtD
Tretinoin—Syncope—Doxorubicin—testicular cancer	5.94e-05	0.000234	CcSEcCtD
Tretinoin—Confusional state—Epirubicin—testicular cancer	5.89e-05	0.000232	CcSEcCtD
Tretinoin—Palpitations—Doxorubicin—testicular cancer	5.85e-05	0.000231	CcSEcCtD
Tretinoin—Oedema—Epirubicin—testicular cancer	5.84e-05	0.00023	CcSEcCtD
Tretinoin—Anaphylactic shock—Epirubicin—testicular cancer	5.84e-05	0.00023	CcSEcCtD
Tretinoin—Hypotension—Methotrexate—testicular cancer	5.83e-05	0.00023	CcSEcCtD
Tretinoin—Loss of consciousness—Doxorubicin—testicular cancer	5.82e-05	0.000229	CcSEcCtD
Tretinoin—Infection—Epirubicin—testicular cancer	5.8e-05	0.000229	CcSEcCtD
Tretinoin—Cough—Doxorubicin—testicular cancer	5.78e-05	0.000228	CcSEcCtD
Tretinoin—Shock—Epirubicin—testicular cancer	5.74e-05	0.000226	CcSEcCtD
Tretinoin—Convulsion—Doxorubicin—testicular cancer	5.74e-05	0.000226	CcSEcCtD
Tretinoin—Nervous system disorder—Epirubicin—testicular cancer	5.73e-05	0.000226	CcSEcCtD
Tretinoin—Thrombocytopenia—Epirubicin—testicular cancer	5.72e-05	0.000225	CcSEcCtD
Tretinoin—Hypertension—Doxorubicin—testicular cancer	5.72e-05	0.000225	CcSEcCtD
Tretinoin—Tachycardia—Epirubicin—testicular cancer	5.7e-05	0.000225	CcSEcCtD
Tretinoin—Musculoskeletal discomfort—Methotrexate—testicular cancer	5.68e-05	0.000224	CcSEcCtD
Tretinoin—Skin disorder—Epirubicin—testicular cancer	5.67e-05	0.000224	CcSEcCtD
Tretinoin—Hyperhidrosis—Epirubicin—testicular cancer	5.64e-05	0.000222	CcSEcCtD
Tretinoin—Insomnia—Methotrexate—testicular cancer	5.64e-05	0.000222	CcSEcCtD
Tretinoin—Chest pain—Doxorubicin—testicular cancer	5.64e-05	0.000222	CcSEcCtD
Tretinoin—Arthralgia—Doxorubicin—testicular cancer	5.64e-05	0.000222	CcSEcCtD
Tretinoin—Myalgia—Doxorubicin—testicular cancer	5.64e-05	0.000222	CcSEcCtD
Tretinoin—Anxiety—Doxorubicin—testicular cancer	5.62e-05	0.000221	CcSEcCtD
Tretinoin—Paraesthesia—Methotrexate—testicular cancer	5.6e-05	0.000221	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	5.6e-05	0.000221	CcSEcCtD
Tretinoin—Discomfort—Doxorubicin—testicular cancer	5.57e-05	0.000219	CcSEcCtD
Tretinoin—Anorexia—Epirubicin—testicular cancer	5.57e-05	0.000219	CcSEcCtD
Tretinoin—Dyspnoea—Methotrexate—testicular cancer	5.56e-05	0.000219	CcSEcCtD
Tretinoin—Somnolence—Methotrexate—testicular cancer	5.55e-05	0.000219	CcSEcCtD
Tretinoin—Dry mouth—Doxorubicin—testicular cancer	5.51e-05	0.000217	CcSEcCtD
Tretinoin—Dyspepsia—Methotrexate—testicular cancer	5.49e-05	0.000216	CcSEcCtD
Tretinoin—Hypotension—Epirubicin—testicular cancer	5.46e-05	0.000215	CcSEcCtD
Tretinoin—Confusional state—Doxorubicin—testicular cancer	5.45e-05	0.000215	CcSEcCtD
Tretinoin—Decreased appetite—Methotrexate—testicular cancer	5.42e-05	0.000214	CcSEcCtD
Tretinoin—Anaphylactic shock—Doxorubicin—testicular cancer	5.4e-05	0.000213	CcSEcCtD
Tretinoin—Oedema—Doxorubicin—testicular cancer	5.4e-05	0.000213	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Methotrexate—testicular cancer	5.39e-05	0.000212	CcSEcCtD
Tretinoin—Fatigue—Methotrexate—testicular cancer	5.38e-05	0.000212	CcSEcCtD
Tretinoin—Infection—Doxorubicin—testicular cancer	5.37e-05	0.000212	CcSEcCtD
Tretinoin—Pain—Methotrexate—testicular cancer	5.34e-05	0.00021	CcSEcCtD
Tretinoin—Musculoskeletal discomfort—Epirubicin—testicular cancer	5.32e-05	0.00021	CcSEcCtD
Tretinoin—Shock—Doxorubicin—testicular cancer	5.32e-05	0.000209	CcSEcCtD
Tretinoin—Nervous system disorder—Doxorubicin—testicular cancer	5.3e-05	0.000209	CcSEcCtD
Tretinoin—Thrombocytopenia—Doxorubicin—testicular cancer	5.29e-05	0.000208	CcSEcCtD
Tretinoin—Insomnia—Epirubicin—testicular cancer	5.28e-05	0.000208	CcSEcCtD
Tretinoin—Tachycardia—Doxorubicin—testicular cancer	5.27e-05	0.000208	CcSEcCtD
Tretinoin—Skin disorder—Doxorubicin—testicular cancer	5.25e-05	0.000207	CcSEcCtD
Tretinoin—Paraesthesia—Epirubicin—testicular cancer	5.24e-05	0.000207	CcSEcCtD
Tretinoin—Hyperhidrosis—Doxorubicin—testicular cancer	5.22e-05	0.000206	CcSEcCtD
Tretinoin—Dyspnoea—Epirubicin—testicular cancer	5.21e-05	0.000205	CcSEcCtD
Tretinoin—Somnolence—Epirubicin—testicular cancer	5.19e-05	0.000205	CcSEcCtD
Tretinoin—Anorexia—Doxorubicin—testicular cancer	5.15e-05	0.000203	CcSEcCtD
Tretinoin—Feeling abnormal—Methotrexate—testicular cancer	5.14e-05	0.000203	CcSEcCtD
Tretinoin—Dyspepsia—Epirubicin—testicular cancer	5.14e-05	0.000203	CcSEcCtD
Tretinoin—Gastrointestinal pain—Methotrexate—testicular cancer	5.1e-05	0.000201	CcSEcCtD
Tretinoin—Decreased appetite—Epirubicin—testicular cancer	5.08e-05	0.0002	CcSEcCtD
Tretinoin—Hypotension—Doxorubicin—testicular cancer	5.05e-05	0.000199	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Epirubicin—testicular cancer	5.04e-05	0.000199	CcSEcCtD
Tretinoin—Fatigue—Epirubicin—testicular cancer	5.03e-05	0.000198	CcSEcCtD
Tretinoin—Constipation—Epirubicin—testicular cancer	4.99e-05	0.000197	CcSEcCtD
Tretinoin—Pain—Epirubicin—testicular cancer	4.99e-05	0.000197	CcSEcCtD
Tretinoin—Urticaria—Methotrexate—testicular cancer	4.96e-05	0.000195	CcSEcCtD
Tretinoin—Abdominal pain—Methotrexate—testicular cancer	4.93e-05	0.000194	CcSEcCtD
Tretinoin—Body temperature increased—Methotrexate—testicular cancer	4.93e-05	0.000194	CcSEcCtD
Tretinoin—Musculoskeletal discomfort—Doxorubicin—testicular cancer	4.92e-05	0.000194	CcSEcCtD
Tretinoin—Insomnia—Doxorubicin—testicular cancer	4.89e-05	0.000193	CcSEcCtD
Tretinoin—Paraesthesia—Doxorubicin—testicular cancer	4.85e-05	0.000191	CcSEcCtD
Tretinoin—Dyspnoea—Doxorubicin—testicular cancer	4.82e-05	0.00019	CcSEcCtD
Tretinoin—Feeling abnormal—Epirubicin—testicular cancer	4.81e-05	0.00019	CcSEcCtD
Tretinoin—Somnolence—Doxorubicin—testicular cancer	4.8e-05	0.000189	CcSEcCtD
Tretinoin—Gastrointestinal pain—Epirubicin—testicular cancer	4.77e-05	0.000188	CcSEcCtD
Tretinoin—Dyspepsia—Doxorubicin—testicular cancer	4.76e-05	0.000187	CcSEcCtD
Tretinoin—Decreased appetite—Doxorubicin—testicular cancer	4.7e-05	0.000185	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Doxorubicin—testicular cancer	4.66e-05	0.000184	CcSEcCtD
Tretinoin—Fatigue—Doxorubicin—testicular cancer	4.66e-05	0.000184	CcSEcCtD
Tretinoin—Urticaria—Epirubicin—testicular cancer	4.64e-05	0.000183	CcSEcCtD
Tretinoin—Pain—Doxorubicin—testicular cancer	4.62e-05	0.000182	CcSEcCtD
Tretinoin—Constipation—Doxorubicin—testicular cancer	4.62e-05	0.000182	CcSEcCtD
Tretinoin—Body temperature increased—Epirubicin—testicular cancer	4.62e-05	0.000182	CcSEcCtD
Tretinoin—Abdominal pain—Epirubicin—testicular cancer	4.62e-05	0.000182	CcSEcCtD
Tretinoin—Hypersensitivity—Methotrexate—testicular cancer	4.6e-05	0.000181	CcSEcCtD
Tretinoin—Asthenia—Methotrexate—testicular cancer	4.48e-05	0.000176	CcSEcCtD
Tretinoin—Feeling abnormal—Doxorubicin—testicular cancer	4.45e-05	0.000175	CcSEcCtD
Tretinoin—Gastrointestinal pain—Doxorubicin—testicular cancer	4.42e-05	0.000174	CcSEcCtD
Tretinoin—Pruritus—Methotrexate—testicular cancer	4.41e-05	0.000174	CcSEcCtD
Tretinoin—Hypersensitivity—Epirubicin—testicular cancer	4.3e-05	0.00017	CcSEcCtD
Tretinoin—Urticaria—Doxorubicin—testicular cancer	4.29e-05	0.000169	CcSEcCtD
Tretinoin—Abdominal pain—Doxorubicin—testicular cancer	4.27e-05	0.000168	CcSEcCtD
Tretinoin—Body temperature increased—Doxorubicin—testicular cancer	4.27e-05	0.000168	CcSEcCtD
Tretinoin—Diarrhoea—Methotrexate—testicular cancer	4.27e-05	0.000168	CcSEcCtD
Tretinoin—Asthenia—Epirubicin—testicular cancer	4.19e-05	0.000165	CcSEcCtD
Tretinoin—Pruritus—Epirubicin—testicular cancer	4.13e-05	0.000163	CcSEcCtD
Tretinoin—Dizziness—Methotrexate—testicular cancer	4.13e-05	0.000163	CcSEcCtD
Tretinoin—Diarrhoea—Epirubicin—testicular cancer	4e-05	0.000157	CcSEcCtD
Tretinoin—Hypersensitivity—Doxorubicin—testicular cancer	3.98e-05	0.000157	CcSEcCtD
Tretinoin—Vomiting—Methotrexate—testicular cancer	3.97e-05	0.000156	CcSEcCtD
Tretinoin—Rash—Methotrexate—testicular cancer	3.93e-05	0.000155	CcSEcCtD
Tretinoin—Dermatitis—Methotrexate—testicular cancer	3.93e-05	0.000155	CcSEcCtD
Tretinoin—Headache—Methotrexate—testicular cancer	3.91e-05	0.000154	CcSEcCtD
Tretinoin—Asthenia—Doxorubicin—testicular cancer	3.88e-05	0.000153	CcSEcCtD
Tretinoin—Dizziness—Epirubicin—testicular cancer	3.86e-05	0.000152	CcSEcCtD
Tretinoin—Pruritus—Doxorubicin—testicular cancer	3.82e-05	0.000151	CcSEcCtD
Tretinoin—Vomiting—Epirubicin—testicular cancer	3.71e-05	0.000146	CcSEcCtD
Tretinoin—Nausea—Methotrexate—testicular cancer	3.71e-05	0.000146	CcSEcCtD
Tretinoin—Diarrhoea—Doxorubicin—testicular cancer	3.7e-05	0.000146	CcSEcCtD
Tretinoin—Rash—Epirubicin—testicular cancer	3.68e-05	0.000145	CcSEcCtD
Tretinoin—Dermatitis—Epirubicin—testicular cancer	3.68e-05	0.000145	CcSEcCtD
Tretinoin—Headache—Epirubicin—testicular cancer	3.66e-05	0.000144	CcSEcCtD
Tretinoin—Dizziness—Doxorubicin—testicular cancer	3.57e-05	0.000141	CcSEcCtD
Tretinoin—Nausea—Epirubicin—testicular cancer	3.47e-05	0.000137	CcSEcCtD
Tretinoin—Vomiting—Doxorubicin—testicular cancer	3.44e-05	0.000135	CcSEcCtD
Tretinoin—Rash—Doxorubicin—testicular cancer	3.41e-05	0.000134	CcSEcCtD
Tretinoin—Dermatitis—Doxorubicin—testicular cancer	3.4e-05	0.000134	CcSEcCtD
Tretinoin—Headache—Doxorubicin—testicular cancer	3.38e-05	0.000133	CcSEcCtD
Tretinoin—Nausea—Doxorubicin—testicular cancer	3.21e-05	0.000126	CcSEcCtD
